Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies-Reference-Cited by-同舟云学术

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies

Published:2019-09-17 Issue:10 Volume:59 Page:1788-1801
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Ashina Messoud¹^ORCID,Vasudeva Raghavendra²,Jin Leah³,Lombard Louise²,Gray Elizabeth⁴,Doty Erin G.²,Yunes‐Medina Laura²,Kinchen Kraig S.²,Tassorelli Cristina⁵⁶

Affiliation:

1. Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

2. Lilly Corporate Center Eli Lilly and Company Indianapolis IN USA

3. Covance Chiltern Princeton NJ USA

4. Eli Lilly Canada Inc Toronto ON Canada

5. Headache Science Centre IRCCS C. Mondino Foundation Pavia Italy

6. Department of Brain and Behavioral Sciences University of Pavia Pavia Italy

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link